ArticleClinical cardiology2026
Prognostic Value of HALP Score in Rheumatic Mitral Stenosis: A Long-Term Follow-up Study.
Article in Clinical cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Reconsidering the Prognostic Role of the HALP Score in Rheumatic Mitral Stenosis.Clinical cardiology · 2026Article
- Methodological Considerations in Assessing HALP Score as a Prognostic Marker in Rheumatic Mitral Stenosis.Clinical cardiology · 2026Article
- Prognostic Value of HALP Score in Rheumatic Mitral Stenosis: A Long-Term Follow-Up Study.Clinical cardiology · 2026Article
- Methodological Considerations on the Prognostic Value of HALP Score in Rheumatic Mitral Stenosis.Clinical cardiology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the prognostic value of the hemoglobin-albumin-lymphocyte-platelet (HALP) score in patients with rheumatic mitral stenosis (RMS).
methodsA total of 169 patients with RMS were retrospectively analyzed over a median follow-up period of 124 months (IQR: 96-148). The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE). The predictive performance of the HALP score was assessed using receiver operating characteristic (ROC) analysis, Cox regression, and Kaplan-Meier survival analysis.
resultsThe HALP score demonstrated a modest but statistically significant ability to predict MACCE (AUC = 0.644, p = 0.037). The optimal cut-off value was 35.65, with a sensitivity of 60.4% and specificity of 38.1%. Patients with lower HALP scores had a significantly higher incidence of MACCE (log-rank p = 0.015). However, in multivariable analysis, the HALP score was not identified as an independent predictor (p = 0.076).
conclusionThe HALP score may serve as a simple and cost-effective complementary tool for risk stratification in patients with RMS. However, its prognostic value appears limited when used alone, and it should be interpreted alongside established clinical and echocardiographic parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.